SubsidieMeestersLILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair Loss
LILY is a portable device that prevents chemotherapy-induced hair loss by using localized microvasculature compression therapy to inhibit drug delivery to hair follicles.
Projectdetails
Introduction
Chemotherapy-induced alopecia (CIA) is hair loss associated with chemotherapy treatment for cancer. LILY is a portable, comfortable, and effective CIA prevention device that uses localized microvasculature compression therapy (LMCT) to prevent CIA.
Mechanism of Action
The LILY device uses this unique LMCT technique to reduce perfusion at the scalp and prevent the destructive action of chemotherapy on hair follicles.
By applying a consistent low-level pressure (between 35 and 60 mmHg) to the local micro blood vessels, which could deliver chemotherapy drugs to fast-dividing hair follicles, the vessels are temporarily compressed, inhibiting drug delivery.
Device Design
The device comprises a proprietary pneumatic bladder network design and soft robotics system with the ability to non-invasively induce vasoconstriction in superficial vessels of the scalp to mechanically control tissue perfusion.
Additionally, it features an electronic control system for both patient management of the system and real-time feedback into the treatment protocol.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 4.107.666 |
Tijdlijn
| Startdatum | 1-10-2023 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- LUMINATE MEDICAL LIMITEDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
LIACFLASH: a life changing IOeRT technology for oncology careLIACFLASH is an innovative IOeRT system leveraging the FLASH effect to deliver high radiation doses that effectively target tumors while minimizing damage to surrounding healthy tissue. | EIC Accelerator | € 2.499.962 | 2022 | Details |
Development of a natural therapeutic treatment for late-stage lung cancer patientsCeltic Biotech aims to conduct Phase I Part 3 trials for CB24, a home-administered treatment for NSCLC, to secure regulatory approval and establish it as a safe, effective cancer therapy. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Best-in-class canceR dIaGnostic cHip for patient sTratification.The RUBYchip is a microfluidic liquid biopsy device that isolates and analyzes cancer cells from blood samples, enabling efficient and reliable monitoring of cancer progression. | EIC Accelerator | € 2.497.880 | 2022 | Details |
iLoF: AI-augmented photonics to identify and quantify disease biomarkersiLoF is developing an AI-driven platform to create a personalized drug discovery tool for Alzheimer’s disease by analyzing biological samples for patient-specific signatures. | EIC Accelerator | € 2.495.850 | 2023 | Details |
Laser bioprinting device and in vivo applicationsPhosPrint's D-LIB platform uses a laser bioprinter for precise in-vivo tissue printing, aiming to enhance surgical outcomes in bladder cancer patients through real-time tissue engineering. | EIC Accelerator | € 2.000.560 | 2023 | Details |
LIACFLASH: a life changing IOeRT technology for oncology care
LIACFLASH is an innovative IOeRT system leveraging the FLASH effect to deliver high radiation doses that effectively target tumors while minimizing damage to surrounding healthy tissue.
Development of a natural therapeutic treatment for late-stage lung cancer patients
Celtic Biotech aims to conduct Phase I Part 3 trials for CB24, a home-administered treatment for NSCLC, to secure regulatory approval and establish it as a safe, effective cancer therapy.
Best-in-class canceR dIaGnostic cHip for patient sTratification.
The RUBYchip is a microfluidic liquid biopsy device that isolates and analyzes cancer cells from blood samples, enabling efficient and reliable monitoring of cancer progression.
iLoF: AI-augmented photonics to identify and quantify disease biomarkers
iLoF is developing an AI-driven platform to create a personalized drug discovery tool for Alzheimer’s disease by analyzing biological samples for patient-specific signatures.
Laser bioprinting device and in vivo applications
PhosPrint's D-LIB platform uses a laser bioprinter for precise in-vivo tissue printing, aiming to enhance surgical outcomes in bladder cancer patients through real-time tissue engineering.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
NeuroProtect – A novel therapy to prevent Chemotherapy-Induced Peripheral NeuropathyThe NeuroProtect project aims to prevent chemotherapy-induced peripheral neuropathy by using Localised Microvascular Compression Therapy to reduce drug delivery to peripheral nerves during treatment. | ERC Proof of... | € 150.000 | 2023 | Details |
Live biotherapeutics to potentiate cancer immunotherapyThe project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models. | ERC Proof of... | € 150.000 | 2023 | Details |
Deep Label-Free Cell Imaging of Liquid Biopsies for Cancer MonitoringDevelop and commercialize a label-free interferometric phase microscopy device with AI for cost-effective cancer diagnosis and monitoring via liquid biopsies. | ERC Proof of... | € 150.000 | 2023 | Details |
Closed-Loop and multisEnsing delIvery tool for controlled Laser Ablation of tumorsThe ERC LASER OPTIMAL project aims to develop a closed-loop control platform for laser ablation with fiber optic sensors to enhance precision in cancer treatment and facilitate market readiness. | ERC Proof of... | € 150.000 | 2022 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
NeuroProtect – A novel therapy to prevent Chemotherapy-Induced Peripheral Neuropathy
The NeuroProtect project aims to prevent chemotherapy-induced peripheral neuropathy by using Localised Microvascular Compression Therapy to reduce drug delivery to peripheral nerves during treatment.
Live biotherapeutics to potentiate cancer immunotherapy
The project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models.
Deep Label-Free Cell Imaging of Liquid Biopsies for Cancer Monitoring
Develop and commercialize a label-free interferometric phase microscopy device with AI for cost-effective cancer diagnosis and monitoring via liquid biopsies.
Closed-Loop and multisEnsing delIvery tool for controlled Laser Ablation of tumors
The ERC LASER OPTIMAL project aims to develop a closed-loop control platform for laser ablation with fiber optic sensors to enhance precision in cancer treatment and facilitate market readiness.
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.